Testing effectiveness (Phase 2)Ended earlyNCT02349633What this trial is testingStudy For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)Who this might be right forNon-Small Cell Lung Cancer Pfizer 65
Testing effectiveness (Phase 2)WithdrawnNCT02297425What this trial is testingPatients With EGFRm (Epidermal Growth Factor Receptor Mutant) Lung CancerWho this might be right forAdvanced EGFRm (Del 19 or L858R +/- T790M) NSCLC Pfizer